Search Results
Found 4 results for "sweden" across articles, medicines, trials, companies and the glossary
Regulatory Affairs
Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots
The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines — a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.